Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril-valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF)

Next Previous
Search
Trial Profile

A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril-valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Enalapril
  • Indications Decompensated heart failure
  • Focus Therapeutic Use
  • Acronyms PIONEER-HF
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 01 Sep 2020 Results published in the Journal of the American College of Cardiology
    • 30 Mar 2020 Results (n=15,038) of meta-analysis exploring angioedema in the 6 clinical trials (PARADIGM-HF, PIONEER, TITRATION, EVALUATE-HF & PARAGON-HF) and in real-world pharmacovigilance data, presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology.
    • 18 Nov 2019 Results assessing efficacy and safety of Sacubitril/Valsartan in Acute Decompensated Heart Failure, presented at the American Heart Association Scientific Sessions 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top